Pimecrolimus | 1593

Pimecrolimus is a cell-selective inhibitor of inflammatory cytokines developed for the treatment of inflammatory skin diseases, such as allergic contact dermatitis, atopic dermatitis, plaque-type psoriasis, and irritant contact dermatitis. It reduces the production of inflammatory cytokines in T cells and mast cells and inhibits the release of preformed inflammatory mediators from mast cells.

Pimecrolimus is a cell-selective inhibitor of inflammatory cytokines developed for the treatment of inflammatory skin diseases, such as allergic contact dermatitis, atopic dermatitis, plaque-type psoriasis, and irritant contact dermatitis.

1593 | Pimecrolimus DataSheet

Alternate Name/Synonyms: Elidel, SDZ-ASM-981

Appearance: White solid

Formulation: N/A

CAS Number: 137071-32-0

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: No

Molecular Formula: C₄₃H₆₈ClNO₁₁

Molecular Weight: 810.45

Cell-Permeable?: Yes

Purity: ≥98%

Solubilities: DMSO (25 mg/ml) or EtOH (25 mg/ml)

Handling: Protect from light and moisture

Country of Origin: USA

Tag Line: Inflammatory cytokines inhibitor

MDL Number: MFCD00901792

PubChem CID: 6447131

SMILES: CCC1C=C(CC(CC(C2C(CC(C(O2)(C(=O)C(=O)N3CCCCC3C(=O)OC(C(C(CC1=O)O)C)C(=CC4CCC(C(C4)OC)Cl)C)O)C)OC)OC)C)C

InChi: InChI=1S/C43H68ClNO11/c1-10-30-18-24(2)17-25(3)19-36(53-8)39-37(54-9)21-27(5)43(51,56-39)40(48)41(49)45-16-12-11-13-32(45)42(50)55-38(28(6)33(46)23-34(30)47)26(4)20-29-14-15-31(44)35(22-29)52-7/h18,20,25,27-33,35-39,46,51H,10-17,19,21-23H2,1-9H3/b24-18-,26-20+/t25-,27+,28+,29-,30+,31-,32-,33-,35+,36-,37-,38+,39+,43+/m0/s1

InChi Key: KASDHRXLYQOAKZ-OLHLVPFQSA-N